Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $16.4M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −13 vs. previous quarter
- 45
- 13F valueReported value at the end of Q2 2026
- $5.05M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$75.8M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.87M
- Shares sold short
- Change
- +398.1K
- +6.2% vs. previous
- Days to cover
- 16.99
- At average daily volume
Superinvestors holding JSPR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding JSPR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Jasper Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 22, 2026 (view filing)7:10 PM ET | Jul 20 | 2 days | Ros Matthew EChief Operating Officer | PPurchaseVoting Common Stock | +53.7K | – | – | –881 after | Derivative |
| Jul 20, 2026 (view filing)8:38 PM ET | Jul 20 | Same day | Crutcher Patrick JDirector | PPurchaseVoting Common Stock | +888 | – | – | –888 after | Derivative |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Wiggans Thomas GDirector | PPurchaseVoting Common Stock | +41.0K | $2.43 | +$99.6K | New position41.0K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Wiggans Thomas GDirector | PPurchaseVoting Common Stock | +41.0K | – | – | –41.0K after | DerivativeDuplicate filing |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Lucas SvetlanaDirector | PPurchaseVoting Common Stock | +20.0K | $2.43 | +$48.6K | New position20.0K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Lucas SvetlanaDirector | PPurchaseVoting Common Stock | +20.0K | – | – | –20.0K after | Derivative |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Martell RonPresident and CEO | PPurchaseVoting Common Stock | +41.0K | $2.43 | +$99.6K | +123.8%74.1K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Martell RonPresident and CEO | PPurchaseVoting Common Stock | +41.0K | – | – | –41.0K after | Derivative |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Shizuru Judith AnneDirector | PPurchaseVoting Common Stock | +41.0K | $2.43 | +$99.6K | +35.4%156.9K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Shizuru Judith AnneDirector | PPurchaseVoting Common Stock | +41.0K | – | – | –41.0K after | Derivative |
Top 10 13F holders, Q2 2026
See all 45 holdersThe largest institutional positions in Jasper Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 2,668,395 | $1.12M | 0.69% | 00.0% | Unchanged |
| Acorn Capital Advisors, LLC | 1,438,159 | $604.0K | 0.16% | +26,667+1.9% | Added |
| Kingdon Capital Management, L.L.C. | 1,352,106 | $569.2K | 0.08% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,172,021 | $493.4K | 0.00% | −5760.0% | Reduced |
| Rock Springs Capital Management LP | 1,100,726 | $463.4K | 0.02% | 00.0% | Unchanged |
| Carlyle Group Inc. | 1,066,189 | $448.9K | 0.00% | 00.0% | Unchanged |
| Gsa Capital Partners LLP | 534,697 | $225.0K | 0.01% | +515,613+2,701.8% | Added |
| Millennium Management LLC | 486,933 | $205.0K | 0.00% | −1,130,598−69.9% | Reduced |
| Lion Point Capital, LP | 465,000 | $195.8K | 0.94% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 263,808 | $111.1K | 0.00% | −53,869−17.0% | Reduced |
Holders of 5% or more of JSPR
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Jasper Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 13G | 9.90%3.36M shares | +0.02 ppfrom 9.88% | Jan 27, 20236 filings | Aug 17, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 7.10%2.06M shares | New | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
| Bank of America Corp | 13G | 6.40%2.13M shares | New | Oct 28, 20261 filing | Oct 28, 2026 | SEC |
| Acorn Bioventures, L.P. | 13G/A | 5.30%1.49M shares | −1.10 ppfrom 6.40% | Dec 2, 20252 filings | Jan 26, 2026 | SEC |